In the light of todays stock activity consider the

In the light of todays stock activity consider the following.

Notes from a different source: 5 points
1. The Company also has successfully completed a Phase 2 trial of Brilacidin in Oral Mucositis, aligning with the FDA on a planned Phase 3 program. "

2. Development of an optimized oral rinse formulation is in progress, with potential to progress to Phase 3 clinical trials in 2022, pending completion of drug formulation work and securing sufficient drug supply and working capital. ..

3. We have ordered Brilacidin API (active pharmaceutical ingredient) for delivery in January 2022, for use in our planned oral mucositis Phase 3 clinical study...

4. As of June 30, 2021, we had approximately $10.2 million in cash compared to $6.0 million of cash as of June 30, 2020, and as of the date of this filing, we have approximately $11.3 million in cash. We currently anticipate that future budget expenditures will be approximately $10.2 million for the next 12 months, including approximately $8.2 million for clinical activities, supportive research, and drug product. "

5. Then there waits Kevetrin

Ronald A Phillips